Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China

• 作 者: Can Luo Jianshu Wei Weidong Ha
• 机 构: InstituteofBasicMedicine/Bio-therapeuticDepartment
• 出 处: 中国科学：生命科学英文版
• 发表日期: 2016年4期
• 关键词: 中国科学家 受体基因 抗原 嵌合 基因工程 临床试验 肿瘤免疫 临床疗效 chimeric antigen receptor tumor associated
• 基金项目: supported by Science and Technology Planning Project of Beijing City （Z151100003915076 to Weidong Han）, National Natural Science Foundation of China （31270820, 81230061 to Weidong Han, 81502679 to Can

T cell mediated adoptive immune response has been characterized as the key to anti-tumor immunity. Scientists around the world including in China, have been trying to harness the power of T cells against tumors for decades. Recently, the biosynthetic chim